摘要
目的:评价康复新液辅助治疗消化性溃疡的临床疗效及安全性。方法:通过计算机检索维普、万方、中国知网、生物医学文献、EMBase数据库,筛选出康复新液辅助治疗消化性溃疡的临床随机对照试验,依据Cochrane协作网推荐的质量评价标准评价纳入研究的方法学质量,利用Revman 5.3软件对相关数据进行Meta分析。结果:共纳入12例符合标准的文献共计1181例患者,Meta分析结果示在使用常规西药基础上,联合康复新液治疗能提高临床有效率(RR=1.15,95%CI[1.11,1.20],P<0.00001),胃镜疗效(RR=1.11,95%CI[1.05,1.16],P<0.00001),降低复发率(RR=0.38,95%CI[0.25,0.57],P<0.00001),而且未增加不良反应发生率(RR=1.14,95%CI[0.77,1.69],P=0.50>0.05)。结论:在使用常规西药基础上联合康复新液治疗可进一步改善消化性溃疡的临床疗效并有较好的安全性,因受纳入研究质量影响,其结论仍需高质量的研究进一步论证。
Objective:To evaluate the clinical efficacy and safety of Kangfuxin Liquid in the treatment of peptic ulcer.Methods:Electronic databases including VIP,Wanfang,China National Knowledge Infrastructure,PubMed and EMBase were searched.The randomized controlled clinical trials of Kangfuxin Liquid in the treatment of peptic ulcer were selected,and evaluated according to the quality evaluation criteria recommended by Cochrane,and the relevant data were analyzed by RevMan5.3 software.Results:A total of 12 RCTs involving 1181 patients were included;The results of meta analysis showed that the combined therapy of conventional western medicine with Kangfuxin Liquid could improve the clinical efficiency(RR=1.15,95%CI[1.11,1.20],P<0.00001)and curative effect under gastroscope(RR=1.11,95%CI[1.05,1.16],P<0.00001),and reduce recurrence rate(RR=0.38,95%CI[0.25,0.57],P<0.00001),and did not increase the incidence of adverse reactions(RR=1.14,95%CI[0.77,1.69],P=0.50>0.05).Conclusion:The combined therapy of conventional western medicine with Kangfuxin Liquid could further improve the clinical efficacy of peptic ulcer with a good safety.Due to the influence of the quality of the included studies,the above conclusions need to be conducted by more high-quality research.
作者
禚昌红
张道伟
司国民
ZHUO Chang-hong;ZHANG Dao-wei;SI Guo-min(Shandong University of Traditional Chinese Medicine,Jinan 250355,China;Shouguang Traditional Chinese Medicine Hospital,ShanDong Shouguang 262700;Shandong Provincial Hospital,Jinan 250021,China)
出处
《中国中医基础医学杂志》
CAS
CSCD
北大核心
2021年第9期1409-1413,共5页
JOURNAL OF BASIC CHINESE MEDICINE
基金
国家中医药管理局齐鲁伤寒流派传承工作室建设项目(LPGZS 2012-34)
中医经方准确化及产业化关键技术示范研究(2016CYJS08A013)
山东省中医药科技发展计划项目(2019-0052)。
作者简介
禚昌红(1988-),女,山东临沂人,博士研究生,从事肾病、脑病及脾胃病的中西医结合临床与研究;通讯作者:司国民(1964-),男,山东济南人,教授,主任医师,博士研究生导师,从事肾病、脑病及脾胃病的中西医结合临床与研究,Tel:13808929737,E-mail:sgm977@126.com。